


## Supplementary material

Flisiak R, Zarębska-Michaluk D, Berak H, et al. Treatment of the most difficult-to-cure hepatitis C virus–infected population with sofosbuvir / velpatasvir. *Pol Arch Intern Med.* 2024; 134: 16644. doi:10.20452/pamw.16644

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

**Figure S1.** Sustained virologic response (SVR) after treatment with sofosbuvir/velpatasvir ± ribavirin (SOV/VEL±RBV) in easy-to-cure and difficult-to-cure populations depending on individual factors influencing virological response.



**Figure S2.** Sustained virologic response (SVR) after treatment with sofosbuvir/velpatasvir ± ribavirin (SOV/VEL±RBV) in easy-to-cure and difficult-to-cure populations by combination of factors influencing virological response.

